Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Stays The M&A Course; Snaps Up Niche Mallinckrodt Assets

Executive Summary

India’s Piramal group continues its buying spree, snapping up Mallinckrodt’s intrathecal therapy business, as it seeks limited competition niches to plough deeper into the $20bn-plus global generic injectable hospital drugs market.

You may also be interested in...



Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma

Nandini Piramal, executive director of Piramal Enterprises, discusses how things have shaped the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.

Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma

Nandini Piramal, executive director, Piramal Enterprises, discusses how things have shaped in the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing  "framework" deployed by industry.

Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma

Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel